The DOI matches its Crossref record; 231 of the 232 references it cites were found in a registry or an index.
Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Open accessAbstract
The shared role of amyloid-β (Aβ) deposition in cerebral amyloid angiopathy (CAA) and Alzheimer disease (AD) is arguably the clearest instance of crosstalk between neurodegenerative and cerebrovascular processes. The pathogenic pathways of CAA and AD intersect at the levels of Aβ generation, its circulation within the interstitial fluid and perivascular drainage pathways and its brain clearance, but diverge in their mechanisms of brain injury and disease presentation. Here, we review the evidence for and the pathogenic implications of interactions between CAA and AD. Both pathologies seem to be driven by impaired Aβ clearance, creating conditions for a self-reinforcing cycle of increased vascular Aβ, reduced perivascular clearance and further CAA and AD progression. Despite the close relationship between vascular and plaque Aβ deposition, several factors favour one or the other, such as the carboxy-terminal site of the peptide and specific co-deposited proteins. Amyloid-related imaging abnormalities that have been seen in trials of anti-Aβ immunotherapy are another probable intersection between CAA and AD, representing overload of perivascular clearance pathways and the effects of removing Aβ from CAA-positive vessels. The intersections between CAA and AD point to a crucial role for improving vascular function in the treatment of both diseases and indicate the next steps necessary for identifying therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, brains from COVID patients also show ischemic and hemorrhagic lesions, as well as microglial activation [79], which can be seen in many AD patients with cerebral amyloid angiopathy [80].”
From What would it take to prove that a chronic infection is a causal agent in Alzheimer’s disease? (2025) · cites this paper as [80]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recently, vascular deposits of Aβ peptides (amyloid angiopathy) are increasingly recognized as a common pathology in AD cases, supporting that Aβ peptides circulate within the interstitial fluid, including CSF, and blood vessels through perivascular (e.g. lymphatic) drainage pathways during the crosstalk between the brain and the vascular system [77].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“Recently, vascular deposits of Aβ peptides (amyloid angiopathy) are increasingly recognized as a common pathology in AD cases, supporting that Aβ peptides circulate within the interstitial fluid, including CSF, and blood vessels through perivascular (e.g. lymphatic) drainage pathways during the crosstalk between the brain and the vascular system [77].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“Inflammation does, however, not seem to be a major component in CAA-related microhemorrhage or microinfarction [38], with the exception of a rare clinical subtype: CAA-related inflammation [6].”
From Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy (2021) · cites this paper as [6]
In the citing paper
“AQP4 levels are reduced in CAA; since AQP4 plays a vital role in glymphatic Aβ clearance in AD brain parenchyma, this consequently impairs Aβ clearance [606, 608].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [608]
In the citing paper
“AQP4 levels are reduced in CAA; since AQP4 plays a vital role in glymphatic Aβ clearance in AD brain parenchyma, this consequently impairs Aβ clearance [606, 608].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [608]
In the citing paper
“Chronic inflammation‐induced disruption of the BBB is an early biomarker of human cognitive dysfunction and often leads to dementia, 113 and both Aβ deposits and tau pathology aggravate vascular damage. 114 , 115”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [115]
In the citing paper
“There is overwhelming evidence for cerebrovascular alterations in AD pathology and amyloid-β deposition around leptomeningeal vessels is a hall mark of cerebral amyloid angiopathy, occurring in almost all AD patients”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Greenberg et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Sleep Drives Metabolite Clearance from the Adult Brain
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Sorted by citations
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13859 · Cited by 2,803
Self-citationKnopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
Charidimou, A., Boulouis, G., Frosch, M. P., Baron, J.-C., Pasi, M., Albucher, J. F., Banerjee, G., Barbato, C., Bonneville, F., Brandner, S., et al. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00208-3 · Cited by 723
Self-citationSalloway, S., Chalkias, S., Barkhof, F., Burkett, P., Barakos, J., Purcell, D., Suhy, J., Forrestal, F., Tian, Y., Umans, K., et al. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2021.4161 · Cited by 619
Applications of focused ultrasound in the brain: from thermoablation to drug delivery
Meng, Y., Hynynen, K., & Lipsman, N. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-00418-z · Cited by 528
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Frisoni, G. B., Altomare, D., Thal, D. R., Ribaldi, F., van der Kant, R., Ossenkoppele, R., Blennow, K., Cummings, J., van Duijn, C., Nilsson, P. M., et al. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00533-w · Cited by 513
Microglia use TAM receptors to detect and engulf amyloid β plaques
Huang, Y., Happonen, K. E., Burrola, P. G., O’Connor, C., Hah, N., Huang, L., Nimmerjahn, A., & Lemke, G. (2021) · Nature Immunology · doi:10.1038/s41590-021-00913-5 · Cited by 483
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2024) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 483
Söderberg, L., Johannesson, M., Nygren, P., Laudon, H., Eriksson, F., Osswald, G., Möller, C., & Lannfelt, L. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01308-6 · Cited by 459
Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics
Hampel, H., Elhage, A., Cho, M., Apostolova, L. G., Nicoll, J. A. R., & Atri, A. (2023) · Brain · doi:10.1093/brain/awad188 · Cited by 412
Neuropathology of Alzheimer's Disease
Trejo‐Lopez, J. A., Yachnis, A. T., & Prokop, S. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01146-y · Cited by 419
Alzheimer's disease: From immunotherapy to immunoprevention
Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353
Cerebral blood flow decrease as an early pathological mechanism in Alzheimer's disease
Korte, N., Nortley, R., & Attwell, D. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02215-w · Cited by 365
Tauopathies: new perspectives and challenges
Zhang, Y., Wu, K.-M., Yang, L., Dong, Q., & Yu, J.-T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00533-z · Cited by 323
Prevalence of cerebral amyloid angiopathy: A systematic review and meta‐analysis
Jäkel, L., de Kort, A. M., Klijn, C. J. M., Schreuder, F. H. B. M., & Verbeek, M. M. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12366 · Cited by 331
Single-cell dissection of the human brain vasculature
García, F., Sun, N., Lee, H., Godlewski, B. R., Mathys, H., Galani, K., Zhou, B., Jiang, X., Ng, A. P., Mantero, J. C., et al. (2022) · Nature · doi:10.1038/s41586-022-04521-7 · Cited by 313
Emerging roles of innate and adaptive immunity in Alzheimer’s disease
Chen, X., & Holtzman, D. M. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.016 · Cited by 297
The glymphatic hypothesis: the theory and the evidence
Hladky, S. B., & Barrand, M. A. (2022) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00282-z · Cited by 278
Cognitive impact of COVID-19: looking beyond the short term
Miners, J. S., Kehoe, P. G., & Love, S. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00744-w · Cited by 261
Cellular senescence at the crossroads of inflammation and Alzheimer's disease
Guerrero, A., De Strooper, B., & Arancibia-Cárcamo, I. L. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2021.06.007 · Cited by 236
In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
Tijms, B. M., Vromen, E. M., Mjaavatten, O., Holstege, H. H., Reus, L. M., van der Lee, S. J., Wesenhagen, K. E. J., Lorenzini, L., Vermunt, L., Venkatraghavan, V., et al. (2024) · Nature Aging · doi:10.1038/s43587-023-00550-7 · Cited by 237
Role of Inflammatory Processes in Hemorrhagic Stroke
Ohashi, S. N., DeLong, J. H., Kozberg, M. G., Mazur-Hart, D. J., van Veluw, S. J., Alkayed, N. J., & Sansing, L. H. (2023) · Stroke · doi:10.1161/strokeaha.122.037155 · Cited by 224
Wang, H., Dey, K. K., Chen, P.-C., Li, Y., Niu, M., Cho, J.-H., Wang, X., Bai, B., Jiao, Y., Chepyala, S. R., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00384-6 · Cited by 210
Cerebral small vessel disease and vascular cognitive impairment: from diagnosis to management
Zotin, M. C. Z., Sveikata, L., Viswanathan, A., & Yilmaz, P. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000913 · Cited by 221
Relationship Between Amyloid-β Deposition and Blood–Brain Barrier Dysfunction in Alzheimer’s Disease
Wang, D., Chen, F., Han, Z., Yin, Z., Ge, X., & Lei, P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.695479 · Cited by 208
Aducanumab: Appropriate Use Recommendations Update
Cummings, J. L., Rabinovici, G. D., Atri, A., Aisen, P. S. S., Apostolova, L. G., Hendrix, S. B., Sabbagh, M. N., Selkoe, D. J., Weiner, M. W., & Salloway, S. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.34 · Cited by 204
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Boxer, A. L., & Sperling, R. (2023) · Cell · doi:10.1016/j.cell.2023.09.023 · Cited by 197
Self-citationProgression of cerebral amyloid angiopathy: a pathophysiological framework
Koemans, E. A., Chhatwal, J. P., van Veluw, S. J., van Etten, E. S., van Osch, M. J. P., van Walderveen, M. A. A., Sohrabi, H. R., Kozberg, M. G., Shirzadi, Z., Terwindt, G. M., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00114-x · Cited by 199
Self-citationRole of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Vaz, M., Silva, V., Monteiro, C., & Silvestre, S. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s325026 · Cited by 183
“ARIAs are abnormal findings detected in brain magnetic resonance imaging (MRI) and can present as brain edema or sulcal effusions (ARIA-E) and as intracerebral hemorrhage often accompanied by superficial hemosiderin deposits (ARIA-H).(52) Although the mechanism leading to ARIA remains not fully understood, studies sug…”
BackgroundAmyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease
Zimmer, J. A., Ardayfio, P. A., Wang, H., Khanna, R., Evans, C. D., Lu, M., Sparks, J., Andersen, S. W., Lauzon, S., Nery, E. S. M., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0065 · Cited by 188
Self-citationXiong, M., Jiang, H., Serrano, J. R., Gonzales, E. R., Wang, C., Gratuze, M., Hoyle, R., Bien-Ly, N., Silverman, A. P., Sullivan, P. M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd7522 · Cited by 179
Epidemiology of neurological diseases in older adults
Dumurgier, J., & Tzourio, C. (2020) · Revue Neurologique · doi:10.1016/j.neurol.2020.01.356 · Cited by 183
Andjelkovic, A. V., Situ, M., Citalán‐Madrid, A. F., Stamatovic, S. M., Xiang, J., & Keep, R. F. (2023) · Stroke · doi:10.1161/strokeaha.122.040578 · Cited by 190
Reactive astrocytes: The nexus of pathological and clinical hallmarks of Alzheimer’s disease
Price, B. R., Johnson, L. A., & Norris, C. M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101335 · Cited by 184
Barakos, J. A., Purcell, D. D., Suhy, J., Chalkias, S., Burkett, P., Grassi, C. M., Castrillo‐Viguera, C., Rubino, I., & Vijverberg, E. G. B. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.21 · Cited by 173
Hoscheidt, S. M., Sanderlin, A. H., Baker, L. D., Jung, Y., Lockhart, S. N., Kellar, D., Whitlow, C. T., Hanson, A. J., Friedman, S. D., Register, T. C., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12421 · Cited by 176
Past, present and future role of retinal imaging in neurodegenerative disease
Kashani, A. H., Asanad, S., Chan, J. W., Singer, M., Zhang, J., Sharifi, M., Khansari, M. M., Abdolahi, F., Shi, Y., Biffi, A., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100938 · Cited by 169
Perosa, V., Oltmer, J., Munting, L. P., Freeze, W. M., Auger, C. A., Scherlek, A. A., van der Kouwe, A. J. W., Iglesias, J. E., Atzeni, A., Bacskai, B. J., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02393-1 · Cited by 165
Self-citationRecent advances in the modeling of Alzheimer’s disease
Sasaguri, H., Hashimoto, S., Watamura, N., Sato, K., Takamura, R., Nagata, K., Tsubuki, S., Ohshima, T., Yoshiki, A., Sato, K., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.807473 · Cited by 157
Vascular Cognitive Impairment and Dementia
Wong, E. C., & Chui, H. C. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001124 · Cited by 170
Iadecola, C., Smith, E. E., Anrather, J., Gu, C., Mishra, A., Misra, S., Pérez‐Pinzón, M. A., Shih, A. Y., Sorond, F. A., van Veluw, S. J., et al. (2023) · Stroke · doi:10.1161/str.0000000000000431 · Cited by 161
Withington, C., & Turner, R. S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.862369 · Cited by 158
Regenhardt, R. W., Thon, J. M., Das, A. S., Thon, O. R., Charidimou, A., Viswanathan, A., Gurol, M. E., Chwalisz, B. K., Frosch, M. P., Cho, T. A., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1782 · Cited by 146
Self-citationCogswell, P. M., Barakos, J. A., Barkhof, F., Benzinger, T. L. S., Jack, C. R., Poussaint, T. Y., Raji, C. A., Ramanan, V. K., & Whitlow, C. T. (2022) · American Journal of Neuroradiology · doi:10.3174/ajnr.a7586 · Cited by 150
The Neurovascular Unit Dysfunction in Alzheimer’s Disease
Soto-Rojas, L. O., Pacheco‐Herrero, M., Martínez-Gómez, P. A., Campa-Córdoba, B. B., Apátiga-Pérez, R., Villegas-Rojas, M. M., Harrington, C. R., de la Cruz, F., Garcés‐Ramírez, L., & Luna‐Muñoz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042022 · Cited by 144
Pagano, K., Tomaselli, S., Molinari, H., & Ragona, L. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.619667 · Cited by 139
Zhao, Y., Zeng, C., Li, X., Yang, T., Kuang, X., & Du, J. (2020) · Aging Cell · doi:10.1111/acel.13239 · Cited by 135
Pathological changes within the cerebral vasculature in Alzheimer’s disease: New perspectives
Fisher, R. A., Miners, J. S., & Love, S. (2022) · Brain Pathology · doi:10.1111/bpa.13061 · Cited by 133
Causes and consequences of baseline cerebral blood flow reductions in Alzheimer’s disease
Bracko, O., Hernández, J. C. C., Park, L., Nishimura, N., & Schaffer, C. B. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20982383 · Cited by 127
Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease
Derk, J., Jones, H. E., Como, C., Pawlikowski, B., & Siegenthaler, J. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.703944 · Cited by 120
Gaikwad, S., Senapati, S., Haque, M. A., & Kayed, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13490 · Cited by 117
A practical approach to the management of cerebral amyloid angiopathy
Kozberg, M. G., Perosa, V., Gurol, M. E., & van Veluw, S. J. (2020) · International Journal of Stroke · doi:10.1177/1747493020974464 · Cited by 120
Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease
Ramanan, V. K., Armstrong, M. J., Choudhury, P., Coerver, K. A., Hamilton, R. H., Klein, B. C., Wolk, D. A., Wessels, S. R., & Jones, L. K. (2023) · Neurology · doi:10.1212/wnl.0000000000207757 · Cited by 120
The Interstitial System of the Brain in Health and Disease
Shetty, A. K., & Zanirati, G. (2020) · Aging and Disease · doi:10.14336/ad.2020.0103 · Cited by 121
Border-associated macrophages in the central nervous system
Sun, R., & Jiang, H. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03059-x · Cited by 120
Medin co-aggregates with vascular amyloid-β in Alzheimer’s disease
Wagner, J., Degenhardt, K., Veit, M., Louros, N., Konstantoulea, K., Skodras, A., Wild, K., Liu, P., Obermüller, U., Bansal, V., et al. (2022) · Nature · doi:10.1038/s41586-022-05440-3 · Cited by 110
Evidence and perspectives of cell senescence in neurodegenerative diseases
Si, Z., Sun, L., & Wang, X. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111327 · Cited by 105
García-Morales, V., González-Acedo, A., Melguizo-Rodríguez, L., Pardo-Moreno, T., Costela-Ruiz, V. J., Montiel-Troya, M., & Ramos-Rodríguez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9121910 · Cited by 104
Scopoletin: a review of its pharmacology, pharmacokinetics, and toxicity
Gao, X., Li, X.-Y., Zhang, C.-Y., & Bai, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1268464 · Cited by 114
Ouyang, Q., Liu, K., Zhu, Q., Deng, H., Le, Y., Ouyang, W., Yan, X., Zhou, W., & Tong, J. (2022) · Small · doi:10.1002/smll.202107534 · Cited by 94
Alzheimer's disease pathophysiology in the Retina
Gaire, B. P., Koronyo, Y., Fuchs, D.-T. S., Shi, H., Rentsendorj, A., Danziger, R., Vit, J., Mirzaei, N., Doustar, J., Sheyn, J., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101273 · Cited by 107
The blood–brain barrier: a help and a hindrance
Rust, R., Yin, H. R., Buil, B. A., Sagare, A. P., & Kisler, K. (2025) · Brain · doi:10.1093/brain/awaf068 · Cited by 109
Cogswell, P. M., Andrews, T. J., Barakos, J. A., Barkhof, F., Bash, S., Benayoun, M. D., Chiang, G. C.-Y., Franceschi, A. M., Jack, C. R., Pillai, J. J., et al. (2024) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8469 · Cited by 104
Amyloid-Related Imaging Abnormalities: An Update
Roytman, M., Mashriqi, F., Al-Tawil, K., Schulz, P. E., Zaharchuk, G., Benzinger, T. L. S., & Franceschi, A. M. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.22.28461 · Cited by 99
Michalon, A., Hagenbuch, A., Huy, C., Varela, E., Combaluzier, B., Damy, T., Suhr, O. B., Saraiva, M. J., Höck, C., Nitsch, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23274-x · Cited by 101
Moving beyond amyloid and tau to capture the biological heterogeneity of Alzheimer’s disease
Young‐Pearse, T. L., Lee, H., Hsieh, Y., Chou, V., & Selkoe, D. J. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.03.005 · Cited by 102
Shen, Y., Hua, L., Yeh, C., Shen, L., Ying, M., Zhang, Z., Liu, G., Li, S., Chen, S., Chen, X., et al. (2020) · Theranostics · doi:10.7150/thno.44152 · Cited by 101
Walker, L. C. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-3025 · Cited by 113
Blood–brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy
Kozberg, M. G., Yi, I., Freeze, W. M., Auger, C. A., Scherlek, A. A., Greenberg, S. M., & van Veluw, S. J. (2022) · Brain Communications · doi:10.1093/braincomms/fcac245 · Cited by 94
Self-citationThe pathobiology of neurovascular aging
Santisteban, M. M., & Iadecola, C. (2025) · Neuron · doi:10.1016/j.neuron.2024.12.014 · Cited by 102
The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer’s disease
Su, Q., Guo, J.-H., Zhang, Y.-L., Wang, J., & Zhang, Z.-N. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335829 · Cited by 91
Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti–Amyloid-β Therapy
Agarwal, A., Gupta, V., Brahmbhatt, P., Desai, A., Vibhute, P., Joseph-Mathurin, N., & Bathla, G. (2023) · RadioGraphics · doi:10.1148/rg.230009 · Cited by 90
Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease
Apátiga-Pérez, R., Soto-Rojas, L. O., Campa-Córdoba, B. B., Luna‐Viramontes, N. I., Cuevas, E., Villanueva‐Fierro, I., Ontiveros‐Torres, M. Á., Bravo-Muñoz, M., Flores-Rodríguez, P., Garcés‐Ramírez, L., et al. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00814-4 · Cited by 92
Alzheimer’s disease – the journey of a healthy brain into organ failure
Golde, T. E. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00523-1 · Cited by 98
Villain, N., Planche, V., & Levy, R. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.06.012 · Cited by 87
Brain injury-induced dysfunction of the blood brain barrier as a risk for dementia
Abrahamson, E. E., & Ikonomović, M. D. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113257 · Cited by 91
Wu, X., Yang, Z., Zou, J., Gao, H., Shao, Z., Li, C., & Lei, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02179-x · Cited by 88
Exploring cerebral amyloid angiopathy: Insights into pathogenesis, diagnosis, and treatment
Cozza, M., Amadori, L., & Boccardi, V. (2023) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2023.120866 · Cited by 85
Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review
Leipp, F., Vialaret, J., Mohaupt, P., Coppens, S., Jaffuel, A., Niehoff, A., Lehmann, S., & Hirtz, C. (2024) · Brain Communications · doi:10.1093/braincomms/fcae396 · Cited by 88
Heneka, M. T., Gauthier, S. G., Chandekar, S. A., Hahn-Pedersen, J. H., Bentsen, M. A., & Zetterberg, H. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02939-9 · Cited by 97
Jack, C. R., Arani, A., Borowski, B. J., Cash, D. M., Crawford, K., Das, S. R., DeCarli, C., Fletcher, E., Fox, N. C., Gunter, J. L., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14166 · Cited by 82
Microvascular Alterations in Alzheimer's Disease
Steinman, J., Sun, H., & Feng, Z. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.618986 · Cited by 85
Border-associated macrophages as gatekeepers of brain homeostasis and immunity
Vara‐Pérez, M., & Movahedi, K. (2025) · Immunity · doi:10.1016/j.immuni.2025.04.005 · Cited by 83
Uekawa, K., Hattori, Y., Ahn, S. J., Seo, J., Casey, N., Anfray, A., Zhou, P., Luo, W., Anrather, J., Park, L., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00660-1 · Cited by 80
“The mechanisms of amyloid accumulation in the vascular wall have not been fully elucidated, but a leading hypothesis implicates alterations in the vascular clearance of Aβ [2].”
InfluentialVillain, N., Planche, V., Lilamand, M., Cordonnier, C., Soto‐Martin, M., Mollion, H., Bombois, S., & Delrieu, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100094 · Cited by 87
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis
Zhang, S., Gao, Y., Zhao, Y., Huang, T. Y., Zheng, Q., & Wang, X. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00812-5 · Cited by 78
Rabin, J. S., Nichols, E., Joie, R. L., Casaletto, K. B., Palta, P., Dams-O’Connor, K., Kumar, R. G., George, K. M., Satizábal, C. L., Schneider, J. A., et al. (2022) · Brain · doi:10.1093/brain/awac178 · Cited by 79
Lecanemab (Leqembi) is not the right drug for patients with Alzheimer’s disease
Kurkinen, M. T. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/171379 · Cited by 82
Atri, A., Dickerson, B. C., Clevenger, C. K., Karlawish, J. H., Knopman, D. S., Lin, P., Norman, M., Onyike, C. U., Sano, M., Scanland, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14333 · Cited by 84
Kim, S. H., Ahn, J. H., Yang, H. J., Lee, P., Koh, G. Y., & Jeong, Y. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01042-0 · Cited by 79
Carare, R. O., Aldea, R., Agarwal, N., Bacskai, B. J., Bechman, I., Boche, D., Bu, G., Bulters, D. O., Alt, C., Counts, S., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12053 · Cited by 77
Self-citationKaushik, K., van Etten, E. S., Siegerink, B., Kappelle, L. J., Lemstra, A. W., Schreuder, F. H. B. M., Klijn, C. J. M., Peul, W. C., Terwindt, G. M., van Walderveen, M. A. A., et al. (2023) · Stroke · doi:10.1161/strokeaha.122.041690 · Cited by 75
Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction
Wang, H., Nery, E. S. M., Ardayfio, P. A., Khanna, R., Svaldi, D. O., Gueorguieva, I., Shcherbinin, S., Andersen, S. W., Hauck, P. M., Engle, S. E., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70062 · Cited by 77
Self-citationEmerging Roles of Endothelial Nitric Oxide in Preservation of Cognitive Health
Katusic, Z. S., d’Uscio, L. V., & He, T. (2023) · Stroke · doi:10.1161/strokeaha.122.041444 · Cited by 73
Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
VandeVrede, L. A., Gibbs, D. M., KOESTLER, M. E., Joie, R. L., Ljubenkov, P. A., Provost, K., Soleimani‐Meigooni, D. N., Strom, A., Tsoy, E., Rabinovici, G. D., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12101 · Cited by 74
Khoury, N., Pizzo, M. E., Discenza, C. B., Joy, D. A., Tatarakis, D., Todorov, M. I., Negwer, M., Ha, C., de Melo, G. L., Sarrafha, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57108-x · Cited by 78
Three major effects of APOEε4 on Aβ immunotherapy induced ARIA
Foley, K. E., & Wilcock, D. M. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1412006 · Cited by 79
Ponce-Lopez, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094209 · Cited by 75
Metadata
- Authors
- Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Greenberg, Steven M.
- Venue
- Nature Reviews Neurology
- Published
- 2019-12-11
- Volume
- 16
- Issue
- 1
- Pages
- 30-42
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC7268202
- OpenAlex
- W2995183059
- Cited by
- 947
- References
- 232
- Citations by year
- 2026: 146 · 2025: 198 · 2024: 179 · 2023: 154 · 2022: 113 · 2021: 104 · 2020: 52
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG026484)
- National Institute of Neurological Disorders and Stroke (RF1NS110054, R01NS096730, U24NS100591)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- cerebral amyloid angiopathy, Alzheimer's disease, amyloid-beta, amyloid-beta clearance, amyloid-related imaging abnormalities, anti-amyloid immunotherapy, vascular function
- MeSH terms
- Alzheimer Disease, Brain, Humans, Signal Transduction, Amyloid beta-Peptides, Cerebral Amyloid Angiopathy, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
